Q1 EPS Estimate for Enliven Therapeutics Reduced by Analyst

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Enliven Therapeutics in a note issued to investors on Thursday, March 26th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.44) for the quarter, down from their previous forecast of ($0.43). HC Wainwright has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.00) EPS.

Other research analysts have also issued research reports about the stock. Mizuho boosted their target price on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 25th. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.40.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN opened at $38.83 on Monday. Enliven Therapeutics has a 1 year low of $13.30 and a 1 year high of $40.62. The firm’s fifty day simple moving average is $28.56 and its 200 day simple moving average is $23.02. The firm has a market capitalization of $2.32 billion, a PE ratio of -20.88 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06).

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 91,198 shares of the stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.22, for a total value of $2,482,409.56. Following the completion of the sale, the insider directly owned 765,188 shares of the company’s stock, valued at $20,828,417.36. This represents a 10.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the sale, the chief financial officer owned 51,000 shares in the company, valued at $1,508,580. This represents a 16.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 232,180 shares of company stock valued at $6,217,033 in the last 90 days. 25.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after acquiring an additional 594 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Enliven Therapeutics during the fourth quarter valued at approximately $83,000. Quantbot Technologies LP increased its position in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Enliven Therapeutics in the fourth quarter valued at $95,000. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.